Beijing Tongren Eye Center, Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Biomed Environ Sci. 2023 Aug 20;36(8):725-731. doi: 10.3967/bes2023.084.
To investigate the clinical efficacy of dexamethasone vitreous cavity implants (Ozurdex) for the treatment of macular edema (Irvine-Gass Syndrome) after cataract surgery.
Eight patients (eight eyes) with Irvine-Gass syndrome were enrolled for vitreous injections with Ozurdex. The patients included six men (six eyes) and two women (two eyes) with a mean age of 67.12 ± 11.92 years. Changes in the patients best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure were compared before and after treatment.
The mean visual acuity BCVA of the patients was 0.81 ± 0.26 before implantation, which improved to 0.20 ± 0.12, 0.13 ± 0.09, and 0.15 ± 0.13 at 2 weeks, 1 month, and 3 months after implantation, respectively ( < 0.001). The patient's mean CMT before implantation was 703.00 ± 148.88 μm, and it reduced to 258.87 ± 37.40 μm, 236.25 ± 28.74 μm, and 278.00 ± 76.82 μm at 2 weeks, 1 month, and 3 months after implantation, respectively ( < 0.001).
The dexamethasone vitreous cavity implant (Ozurdex) is a safe and effective treatment, which can effectively improve patient's visual acuity and reduce macular edema associated with cataract surgery.
研究地塞米松玻璃体腔植入物（Ozurdex）治疗白内障术后黄斑水肿（Irvine-Gass 综合征）的临床疗效。
对 8 例（8 眼）Irvine-Gass 综合征患者行玻璃体腔注射 Ozurdex，其中男 6 例（6 眼），女 2 例（2 眼），年龄 67.12±11.92 岁。比较治疗前后患者最佳矫正视力（BCVA）、中心黄斑厚度（CMT）和眼压的变化。
患者治疗前平均视力 BCVA 为 0.81±0.26，植入后 2 周、1 个月和 3 个月分别提高至 0.20±0.12、0.13±0.09 和 0.15±0.13（ < 0.001）。患者治疗前平均 CMT 为 703.00±148.88μm，植入后 2 周、1 个月和 3 个月分别降至 258.87±37.40μm、236.25±28.74μm 和 278.00±76.82μm（ < 0.001）。
地塞米松玻璃体腔植入物（Ozurdex）是一种安全有效的治疗方法，可有效提高患者视力，减轻白内障术后黄斑水肿。
